Both BET inhibitors (BETi) and BET degraders (BETd) reduce CSC viability, suppress self-renewal, and enhance chemosensitivity in preclinical models of breast cancer, squamous cell carcinoma, and other tumor types (21, 22, 26–28). Here, DNER is linked to breast carcinoma.